MetaCap

Emergent BioSolutions Inc. (EBS)

NYSE: EBSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

5.05-0.10 (-1.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EBS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$259.65M
EPS (TTM)
-$5.00
52-week range
4.36 – 14.06
Day range
4.98 – 5.24
Volume / Avg
1.39M / 1.11M
Beta
—

52-week range

$4.36$14.06

EBS stock today

On Nov 20, EBS ended the session at $5.05, shedding $0.10 (1.94%), versus the S&P 500's 3.70% decline. At this level, EBS sits near the bottom of its 52-week range of $4.36 to $14.06: 64.1% below the high, set on Jan 7, 2026 and 15.8% above the low. EBS is down 59.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.7%.

Emergent BioSolutions has posted a net loss over the last twelve months (EPS of -$5.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Emergent BioSolutions

Company profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
Headquarters
Gaithersburg, MD
Employees
900
IPO year
2006

Financial highlights

Full financials

In fiscal 2025, Emergent BioSolutions generated $742.9 million in revenue, down 28.8% from fiscal 2024, its first annual decline since 2024. Net income was $52.6 million, for a net margin of 7.1% versus a median of -18.3% in the prior 5 years. Gross margin was 56.1% (up from 34.7%) and operating margin 13.5%.

Emergent BioSolutions annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$742.90M$1.04B$1.05B$1.12B$1.77B
Growth-28.81%-0.54%-6.10%-36.99%+12.45%
Net income$52.60M$-190.60M$-760.50M$-211.60M$219.50M
EPS (diluted)$0.93$-3.60$-14.85$-4.22$4.06

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$10.00+98.02%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 1

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$1.06 vs $-0.45
Surprise
+335.56%

EBS news

All EBS news

Emergent BioSolutions peers

Health Care sector
EBS peer companies
CompanyPrice% ChgMarket capCompare
ALTAltimmune Inc.1.33-5.67%$258.80Mvs EBS
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs EBS
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs EBS
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs EBS
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs EBS
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs EBS
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs EBS
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs EBS

Indexes, lists and sector

Emergent BioSolutions stock FAQ

What is Emergent BioSolutions's stock price today?

EBS last traded at $5.05 as of Nov 20, 4:00 PM EST, down 1.94% on the day. Prices are delayed at least 15 minutes.

Who is Emergent BioSolutions's CEO?

Mr. Joseph C. Papa Jr., M.B.A., R.Ph. is the chief executive officer of Emergent BioSolutions Inc., which has about 900 employees.

What is the EBS 52-week high?

The 52-week high for EBS is $14.06 and the 52-week low is $4.36. The stock is currently 64.1% below its high.

Compare EBS